ARD Podcast

BMJ Group

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange and education. It covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research. Concise scientific communication is encouraged and peer-reviewed proceedings of international meetings are featured. ARD is the official journal of EULAR.

1 Listener

All episodes

Best episodes

Top 10 ARD Podcast Episodes

Goodpods has curated a list of the 10 best ARD Podcast episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to ARD Podcast for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite ARD Podcast episode by adding your comments to the episode page.

A non-pharma approach in systemic lupus erythematosus and systemic sclerosis

ARD Podcast

10/30/23 • 18 min

In this podcast, we discuss the evidence-based EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).
ARD's Social Media Advisor, Professor Laura Andreoli, speaks to Professor Carina Boström and Professor Ioannis Parodis, both from the Karolinska Institutet and the Karolinska University Hospital, Stockholm, Sweden, about their recent paper. Read it on the ARD website: https://ard.bmj.com/content/early/2023/08/23/ard-2023-224416

Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Google Podcasts, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page -https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059 .

1 Listener

Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA

ARD Podcast

01/23/20 • 14 min

Atul Deodhar, from the Oregon Health & Science University, provides an overview of recent clinical trial results in the area of seronegative Spondylarthritis. He presented the 24-week data of Guselkumab in active psoriatic arthritis patients in the DISCOVER-1 study and compared the phase 3 trials in non-radiographic SpA patients on Ixekizumab (COAST-X) and Secukinumab (PREVENT) with up to 52 week data available.

The dose dependent effect of statins on osteoporosis

ARD Podcast

04/22/20 • 12 min

Statins are some of the most commonly prescribed cholesterol-lowering drugs. They act by inhibiting HMG-CoA reductase, the main enzyme in the synthesis of cholesterol. Earlier studies have shown that statins have an osteoprotective effect: a recently published paper has shown that there is a dose-dependent relationship between different kinds of statins with diagnosis of osteoporosis. "We could find an underrepresentation of osteoporosis in low-dose and an overrepresentation in high-dose statin treatment," says first author Dr. Michael Leutner, MSc PhD (Department of Internal Medicine 3, Division of Endocrinology and Metabolism, Medical University of Vienna), who discusses the details of his study with Dr. Paul Studenic in this podcast.

Read the paper: https://ard.bmj.com/content/78/12/1706

The EULAR COVID-19 database and its insights into risk factors

ARD Podcast

03/18/21 • 25 min

The EULAR COVID-19 database and the COVID-19 Global Rheumatology Alliance work together on shared collected data to address the most pertinent questions in regard to risks for people with rheumatic diseases and COVID-19 infection. The latest study confirms already known risk factors for more severe disease and explores associations between treatments and the risk of death.

In this podcast, ARD’s social media editor, Dr Paul Studenic, is joined by Prof. Pedro Machado, from the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, London, UK, to discuss the paper “Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry” (http://dx.doi.org/10.1136/annrheumdis-2020-219498).

Predictors of disease worsening in systemic sclerosis

ARD Podcast

09/15/20 • 11 min

Capturing disease progression in SSc is challenging. Becker and colleagues addressed this problem by identifying predictors of disease worsening in the EUSTAR cohort. ARD's social media advisor Dr. Caroline Ospelt talks to Dr. Mike Becker about the results of this analysis.

Read the paper: ard.bmj.com/content/78/9/1242

Treating Cytokine Storm Syndrome in COVID-19 patients with glucocorticoids and tocilizumab

ARD Podcast

08/06/20 • 23 min

In this podcast, Dr. Paul Studenic speaks to Dr. Sofia Ramiro and Prof. Robert Landewé both engaged in clinical work in the Zuyderland Medical Center in the south of the Netherlands about their clinical study evaluating systemic glucocorticoids and Il-6 blockade as second-line treatment for COVID-19-associated cytokine storm syndrome. They tell the story of the set-up of a peculiar trial using historical patients treated with supportive care as controls to the ‘experimental’ treatment strategy during these unprecedented times of March and April 2020. Link to article: https://ard.bmj.com/content/79/9/1143

Link to EULAR press release: https://www.eular.org/sysModules/obxContent/files/www.eular.2015/1_42291DEB-50E5-49AE-5726D0FAAA83A7D4/eular_glucocorticoids_and_il_6_receptor_can_reduce_covid19_css_related_hospital_mortality_(002).pdf

Immunogenicity of anti-SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases

ARD Podcast

07/29/21 • 20 min

In this podcast, we invite two authors from recent ARD papers dedicated to the efficacy of mRNA vaccines in patients with immunosuppressive therapies. Christophe Richez, Department of Rheumatology, University Medical Center, Bordeaux, France, and ARD's Social Media Advisor, interviews Bimba Hoyer, Department for Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus Kiel, Germany, and Rebecca H Haberman, Division of Rheumatology, University Grossman School of Medicine, New York, USA. They describe their works and offer their thoughts on the current situation in this area and the future. Related content: https://ard.bmj.com/content/early/2021/05/11/annrheumdis-2021-220272

https://ard.bmj.com/content/early/2021/06/07/annrheumdis-2021-220597

A prediction score for individuals at risk to develop rheumatoid arthritis

ARD Podcast

03/25/20 • 12 min

In this podcast recorded at the ACR meeting 2019, Dr. Caroline Ospelt speaks to Prof. Anca Catrina and Dr. Aase Hensvold both of the Division of Rheumatology at the Department of Medicine located at the Karolinska Institute in Stockholm Sweden.

Hensvold et al. developed a prediction score by combining several clinical and blood-based markers that could be useful in predicting which patients with auto-antibodies and musculoskeletal symptoms develop ultrasound-detectable arthritis. These are the first results of an ongoing study on individuals at-risk for rheumatoid arthritis.

Six-week treatment with low-dose prednisolone in patients with painful hand osteoarthritis

ARD Podcast

02/18/20 • 3 min

This randomised, double-blind, placebo-controlled trial by Kroon et al has demonstrated a substantial improvement in painful hand OA with signs of inflammation following six weeks of low-dose prednisolone.

Prediction of radiographic progression using synovitis characteristics

ARD Podcast

03/06/20 • 10 min

Dr. Felice Rivellese from the Center of Experimental Medicine and Rheumatology at the Queen Mary University in London discusses the results of his presentation at the ACR 2019 with Dr. Caroline Ospelt. In a subanalysis of the pathobiology of the Early Arthitis Cohort (PEAC), Rivellese at al could show that B cell-rich synovitis is associated with disease severity and radiographic progression, in particular, if B cell infiltrates persist after cDMARD treatment.

Show more best episodes

FAQ

How many episodes does ARD Podcast have?

ARD Podcast currently has 25 episodes available.

What topics does ARD Podcast cover?

The podcast is about Health & Fitness, Medicine and Podcasts.

What is the most popular episode on ARD Podcast?

The episode title 'A non-pharma approach in systemic lupus erythematosus and systemic sclerosis' is the most popular.

What is the average episode length on ARD Podcast?

The average episode length on ARD Podcast is 14 minutes.

How often are episodes of ARD Podcast released?

Episodes of ARD Podcast are typically released every 103 days, 20 hours.

When was the first episode of ARD Podcast?

The first episode of ARD Podcast was released on Jul 3, 2014.

Show more FAQ

ARD Podcast

BMJ Group

Top 10 ARD Podcast Episodes

FAQ

How many episodes does ARD Podcast have?

What topics does ARD Podcast cover?

What is the most popular episode on ARD Podcast?

What is the average episode length on ARD Podcast?

How often are episodes of ARD Podcast released?

When was the first episode of ARD Podcast?

Comments